×î½ü£¬·è¿ñ±áÖµµÄÈÕÔª£¬Ê¹µÃÈÕ±¾³ÉΪÁË´ó¼Ò³ö¾³ÓεÄÈÈÃÅÄ¿µÄµØ֮ѡ¡£ÈÈÖÔÓÚ¡°¶çÊÖ¡±ÂòÂòÂòµÄÈËÒ²ÓÈΪÐË·Ü£¬ÓÐýÌ屨µÀÔÚÈÕ±¾¸÷´óÉݳÞÆ·µê£¬Ä¿Á¦Ëù¼°¼·ÂúÁËÖйúÈË [1]£¬»¹ÓÐÈ˵÷Ù©¡°ÈÕ±¾»ãÂÊÈà LV ³ÉÁËÍÁÌزú¡± ¡£ÄÄÅÂÏû·Ñ²»Æð´òÕ۵ġ°Â¿¡±£¬È¥Ò©×±µêѪƴÂò»¯×±Æ·¡¢³£±¸Ò©Ò²ÈÃÈËÀÖ¿ªÁË»¨¡£±Ï¾¹È¥ÈÕ±¾ÂÃÓΣ¬Ë×ö¹¥ÂÔʱºòûÊղؼ¸ÆªÒ©×±µê±ØÂòÉñÒ©£¿È»¶ø·îÈ°¸÷λһ¾ä£¬¶ÔÕâЩ±»´µÉÏÌìµÄ¡°ÍøºìÉñÒ©¡±£¬ÕæµÄÒª¶àÁô¼¸¸öÐÄÑÛ¡£ÈÕ±¾ÖÆÔ죬 ÊÕ¸îÖйúÏû·ÑÕß¹ä¹ýÒ©×±µêµÄÅóÓѶ¼ÖªµÀ£¬Ëü¾ÍÏñ°Ù±¦ÏäÒ»ÑùµÄ´æÔÚ£¬³ýÁËÏñÃû×Ö˵µÃÄÇÑùÂôÒ©ºÍ»¯×±Æ·£¬µêÀﻹÓÐÁÕÀÅÂúÄ¿µÄÈÕÓÃÆ·¡¢±£½¡Æ·¡¢Ð¡ÁãʳµÈ£¬µ«·²Ì¤È룬Ǯ°ü×ÜÄܱ»ÌÍ¿Õ¡£²»¹ý£¬ÈýÔ·ݵÄÒ»ÔòÏûÏ¢£¬Èò»ÉÙ°®ÔÚÒ©×±µê¡°±¬Âò¡±µÄÈË£¬×ÅʵÐľªµ¨Õ½ÁËÒ»·¬¡£Ê±¼äµ¹»Øµ½3ÔÂ22ÈÕ£¬Ò©×±µê»õ¼ÜÉϵij£¿ÍСÁÖÖÆÒ©Ðû²¼£¬ÆìÏÂÄܸÄÉÆÈËÌ嵨¹Ì´¼Ë®Æ½µÄ±£½¡Æ·¡°ºìÇúµ¨¹Ì´¼¿ÅÁ£¡±£¬³öÏÖʳÓúóµ¼ÖÂÉöÔ༲²¡µÄ±¨¸æ [2]¡£Ò»Ê±¼ä£¬±£½¡Æ·³É¡°ÖÂÃü¶¾Ò©¡±£¬ÀÏÅÆÖÆÒ©¹«Ë¾Ð¡ÁÖÖÆÒ©Ò²±»ÍÆÉÏ·ç¿ÚÀ˼⡣½ØÖÁ5ÔÂ21ÈÕ£¬¸Ã²úÆ·ÒÑÔì³É5ÀýËÀÍö£¬277ÈËסԺ£¬ÁíÓÐ1599ÈËÇ°ÍùÒ½ÁÆ»ú¹¹¾ÍÕï¡£Äã¿ÉÄÜ»áÒÉ»óºìÇúµ½µ×ÊÇʲô£¿¶ÔÓÚÖйúÈËÀ´Ëµ£¬ËüÆäʵ²¢²»Ä°Éú£¬ag¿·¢_¿·¢Ò»´¥¼´·¢¾³£³ÔµÄ¸¯Èé¡¢²æÉÕ¶¼»áÓõ½£¬¾ÍÊǺìÇú¾ú¼ÄÉúÔÚµ¾Ã×ÉÏ·¢½Í¶øÀ´µÄÒ»ÖÖ΢ÉúÎï·¢½ÍÆ·£¬¿ÉÒÔÓÃ×÷ʳÓÃÉ«ËØ¡¢Ôöζ¼Á¡£ÏÖ´úҽѧ²»ÉÙÑо¿Ö¸³ö£¬ºìÇúµÄÌáÈ¡ÎïÊÇÒ»Öֹ㷺ʹÓ㬾ßÓÐÒ»¶¨½µÖ¬×÷ÓõÄÓªÑø±£½¡Æ· [3]¡£Ò²¾ÍÊÇ˵£¬Óж¾ÐԵĻòÐí²»ÊǺìÇú±¾Éí¡£Ð¡ÁÖÖÆҩҲͨ¹ý¶Ô×ÔÖƺìÇúÔÁϽøÐзÖÎöºó£¬·¢ÏÖÁË·ÇÔ¤Æڵijɷ֡ª¡ªÈíëÇàùËᣬÕâÊÇÒ»ÖÖº¬Óо綾µÄÎïÖÊ£¬¿ÉÄÜÊÇÉú²ú¹ý³ÌÖÐÔâµ½ÁËÎÛȾËùÖ [4]¡£µ«²»¹ÜÔõô˵£¬ÕâÒ»´Î·³µÄÖ³öÈËÃüµÄСÁÖÖÆÒ©£¬Ò²µß¸²Á˲»ÉÙÈ˹ýÍù¶ÔÈÕ±¾ÖÆÔ찲ȫ¡¢ÑϽ÷¡¢Ð§¹û¼ÑµÄºÃÓ¡Ïó¡£Ôø¾£¬³öÓÚ¶Ô½¡¿µÓú·¢¾«Ï¸»¯µÄ×·Ç󣬺ͶÔÈÕ±¾±£½¡Æ·¡¢Ò©Æ·µÄ¹ý·ÖÐÅÈΣ¬²»ÉÙ¡°ÈÕ±¾ÍøºìÉñÒ©¡±ÔÚÉ罻ýÌåÉÏ¿Ú¿ÚÏà´«£¬ÍøÂçÉÏÒ²²»·¦¹Ä´µ¡°ÈÕ±¾ÉñÒ©¡±¡°ÈÕ±¾Ò©×±µê±ØÂò¡±¡°ÈÕ±¾¼ÒÍ¥±Ø±¸Ò©¡±µÄÌû×Ó¡£ag¿·¢_¿·¢Ò»´¥¼´·¢¶ÔÕâЩÌû×Ó½øÐÐÕûÀíºó·¢ÏÖ£¬·ÖÏíƵÂÊ×î¸ßµÄ²úÆ·Ç°ÈýÃû·Ö±ðÊÇ¡°¿ìËÙ»º½âÑÏÖØÍ·ÌÛ¡±µÄ EVE ֹʹƬ¡¢¡°ÏÖ´úÈ˳öÔ¶Ãűر¸Á¼Ò©¡±µÄ°×ÍÃÅÆÔγµÔδ¬Ò©¡¢¶Ô±ÇÑ×»¼ÕßÓС°ÉñЧ¡±µÄ×ôÌÙÖÆÒ©±ÇÑ×ÅçÎí¡£¶ø¸ù¾ÝÈÕ±¾ºñÉúÀͶ¯Ê¡µÄ·ÖÀ࣬ÕâЩ²úÆ·ÒѾ²»ÊôÓÚ±£½¡Æ·µÄ·¶³ë£¬¶øÊÇ·Ç´¦·½Ò©Îï¡£Ë×»°Ëµ¡°ÊÇÒ©Èý·Ö¶¾¡±£¬·²ÊÇÒ©ÎﶼÓÐÒ»¶¨µÄ¸±×÷Óã¬Èç¹û³¤ÆÚ×ÔÐзþÓã¬Æä±³ºóDZ²ØµÄÓÃÒ©·çÏÕ£¬Ô¶±ÈÄãÏëµÃÑÏÖØ¡£¡°ÍøºìÉñÒ©¡±ÃÇ£¬Óж಻¿¿Æ×ÔÚµ±´úÄêÇáµÄ´àƤ´ò¹¤ÈËÑÛÀÌå¼ì±¨¸æÊDz»¸ÒÇáÒ׿´µÄ£¬µ«ÄܶԿ¹½¡¿µ½¹ÂǵÄÁ鵤ÃîÒ©ÊǸҷÅÐijԵġ£Ç°Óк«¹ú·Àâ§ËÀÌײͣ¬ºóÓмÄÍÐÌáÉýÃâÒßÁ¦Ï£ÍûµÄµ°°×·Û£¬´àƤ´ò¹¤ÈËÃǵľÈÃüµ¾²Ý´ÓÀ´Ö»¶à²»ÉÙ¡£¶øÄÇЩ¡°ÈÕ±¾ÉñÒ©¡±Ò²ÊÇÆäÖÐÖ®Ò»£¬ÒòΪËüÃǶ¼Óиö¹²Í¬Ìص㡪¡ª¹¦Ð§½éÉܸ߶ȳ¡¾°»¯£¬ÈÃÈËÒ»ÑÛ±ãÖª²úÆ·¾ßÌåÊǸÉÂïµÄ¡£ÏñÔçЩÄêÁ÷ÐУ¬±»ÓþΪÑÛÒ©Ë®½ì°®ÂíÊ˵ġ°²ÎÌìÇåÁ¹ÑÛÒ©Ë®¡±£¬ºËÐÄÂôµãдµÃÒ»Çå¶þ³þ¡ª¡ª¿ìËÙÏûºìÑÛË¿¡¢³¬¼¶ÇåÁ¹»º½âÑÛÆ£ÀÍ£¬¼«ÖµÄˬ¸ÐÁî²»ÉÙÈËÓùýºó°®²»ÊÍÊÖ¡£È»¶ø£¬Õâ¿î²úÆ·È´ÔÚ2019ÄêÔâµ½Á˼ÓÄôóÎÀÉú²¿¡°È«Ãæ·âɱ¡±£¬ÊµÌåµêϼܡ¢ÍøµêÍ£ÊÛ¡¢º£¹Ø½ûÖ¹½ø¿Ú£¬ÑϸñÏÞÖÆʹÓà [5]¡£ÖÁÓÚËü¾¿¾¹·¸ÁËʲô¡°Ê®¶ñ²»É⡱µÄ×ïÐУ¬¼ÓÄôóÎÀÉú²¿¹ÙÍøҲдµÃ·Ç³£Ã÷È·£¬ÑÛÒ©Ë®Öк¬Óд¦·½Ò©³É·Ö£¬µ«Î´°´ÕÕ´¦·½Ò©µÄºÏ·¨³ÌÐò»ñÅúÉÏÊУ¬¿ÉÄÜ»á´øÀ´ÑÏÖصĽ¡¿µ·çÏÕ¡£ÏñÆäÖк¬Óеļ׻ùÁòËáÐÂ˹µÄÃ÷£¬µÄÈ·¿ÉÒÔÊÕËõÍ«¿×¡¢¸ÄÉƾ۽¹£¬¾ÍºÃÏñÄãÃÐ×ÅÑÛ¾¦ÔÚ¿´¶«Î÷£¬¶Ìʱ¼äÄÚ¿´¶«Î÷¸üÇåÎú£¬µ«³¤Ê±¼äʹÓã¬ÑÛ²¿¼¡Èâ·´¶ø»á¸üÆ£ÀÍ¡¢½ôÕÅ£¬»¹¿ÉÄܳöÏÖÍ·Í´¡¢ÑÛƤ³é´¤ [5][6]¡£´ËÍâ¸Ã¿îÑÛÒ©Ë®»¹Óд¦·½Ò©³É·Ö°±»ù¼ºËᣬ¿ÉÄܵ¼ÖÂÁ÷Àá¡¢ÊÓÁ¦¸Ä±äºÍÍ·Í´µÈ¸±×÷Ó㬲¢²»½¨ÒéËæÒâÀÄÓà [5]¡£¶ÔÒ©Îï³É·Ö°²È«ÐÔ¿¼Á¿Ç·Í×£¬ÔÚÈÕ±¾¡°ÍøºìÉñÒ©¡±Àï²¢·Ç¹ÂÀý¡£¾ßÓÐͬÑùÎÊÌâµÄ£¬»¹Óб»ÊÓΪ¡°Í´¾¾ÈÃüÉñÒ©¡±µÄ EVE ֹʹƬ£¬ÓÐÅ®Éú°²Àûʱ¾Í˵£ºÃ¿´ÎÒ»Âò¾ÍÊÇÒ»´ó°ü£¬ÌÛÆðÀ´µÄʱºòÕæÊÇ°Ñ EVE µ±·¹³Ô¡£ËäÈ» EVE ϵÁÐֹʹƬ¡°ÌùÐÄ¡±Ï¸·ÖΪÁËËĿ¼ÈÓпìËÙ»º½âÑÏÖØÍ·Ì۵ģ¬Ò²ÓÐÕë¶Ô»º½âÉúÀíÆÚÌÛÍ´µÄ£¬µ«±¾ÖʾÍÊDz¼Âå·Ò¡¢±ûÎìõ£ëå¡¢ÎÞË®¿§·ÈÒòºÍÑõ»¯Ã¾ËÄÖֳɷֵÄÅÅÁÐ×éºÏ¡£²¼Âå·ÒÏë±Ø´ó¼ÒºÜÊìϤ£¬µ±Äê»ëÉíËáÍ´¡¢ºíÁüÏñ¡°Í̵¶Æ¬¡±Ê±£¬ÒѾÓëËü½¨Á¢ÆðÁ˹ýÃüµÄ½»Çé¡£ÕæÕýÐèÒª¾¯ÌèµÄ³É·ÖÊDZûÎìõ£ë壬×÷Ϊ´ßÃßÕò¶¨ÀàÒ©ÎËü¾ßÓзdz£ÑÏÖصĸ±×÷Óã¬ÓÐÒ»¶¨¸ÅÂÊÆÆ»µÑªÐ¡°å£¬ÒýÆðÌØ·¢ÐÔѪС°å¼õÉÙÐÔ×Ïñ° [7]¡£ÕýÒòÈç´Ë£¬±ûÎìõ£ëåÔÚ²»ÉÙ¹ú¼Ò¶¼¾ÀúÁË´ÓÒ©Óõ½½ûÓõÄת±ä¡£Ä¿Ç°£¬±ûÎìõ£ëå¾ùδ»ñµÃÖйúÒ©Æ·¼à¶½¹ÜÀí¾Ö¡¢ÃÀ¹úʳƷҩÎï¹ÜÀí¾Ö FDA µÄÅú׼ʹÓ㬰ĴóÀûÑÇÉõÖÁ½«ÆäÁÐΪÁ˶¾Îï³É·Ö [7][8][9]¡£ÔÚÉÙÊý×¼ÐíʹÓõÄÖ÷Òª¹ú¼ÒÀÐÂÎ÷À¼½«Ê¹Ó÷¶Î§ÏÞ¶¨ÔÚÁË´¦·½Ò© [7]£»·´¹ÛÈÕ±¾£¬±ûÎìõ£ëå¿ÉÒÔÏ·ŵ½×÷Ϊ·Ç´¦·½ÕòÍ´Ò©³É·ÖʹÓã¬Ì¬¶È²îÒìÐüÊâ¡£ÈÕ±¾Ò©£¬Ã»ÓÐÏëÏóÖа²È«ÓÐЧ¿ÉÄܺܶàÈ˻᲻½â£¬ÎªÉ¶ÕâЩҩÔÚÈÕ±¾ÄÜÕý³£ÏúÊÛºÍʹÓã¬Ò»Âò»Ø¹úÄÚ×ÔÓþʹæÔÚ·çÏÕ£¿ag¿·¢_¿·¢Ò»´¥¼´·¢ÖªµÀ£¬Ò©Æ·ÔÚÊÀ½ç·¶Î§ÄÚÆÕ±éÖ´ÐзÖÀà¹ÜÀíÖƶȡ£²»Í¬ÓÚÖйú°´ÕÕ´¦·½Ò©ºÍ·Ç´¦·½Ò©»®·Ö [10]£¬ÈÕ±¾µÄÒ©Æ··ÖÀàÌåϵ¸ü¸´ÔÓ¡£³ýÁË´¦·½Ò©£¬ÈÕ±¾ÈËÔÚÒ©µê×ÔÐÐÑ¡ÔñÑ¡¹ºµÄÒ©£¬»¹·ÖΪÁË¡°ÒªÖ¸µ¼Ò½Ò©Æ·¡±ºÍ¡°Ò»°ãÓÃÒ½Ò©Æ·¡±¡£Ç°ÕßÔÚÊÛÂôʱ¸üΪ½÷É÷£¬²»½ö±»°ÚÔÚÄÑÒÔÓÃÊÖÄõ½µÄµØ·½£¬»¹Ö»ÓÐÒ©¼Áʦ²ÅÓÐ×ʸñ¿ªÒ© [11]¡£¡°Ò»°ãÓÃÒ½Ò©Æ·¡±Ôòϸ·ÖµÃ¸üÏêϸ£¬°´ÕÕҩЧ¼°¿ÉÄÜ´æÔڵĸ±×÷ÓÃÓɸߵ½µÍ£¬¹²ÓС°µÚ1Àࡱ¡°Ö¸¶¨µÚ2Àࡱ¡°µÚ2Àࡱ¡°µÚ3ÀࡱҽҩƷËÄÖÖ [11]¡£ÖÆÒ©ÆóÒµ»áÔÚÒ©Æ·Íâ°ü×°ÉÏ»áд¡°µÚ ¡ð ÀàÒ½ËaÆ·¡±µÄ×ÖÑù£¬·½±ã¹ºÂòʱȷÈÏ¡£¹úÄÚÁ÷Ðеġ°ÍøºìÉñÒ©¡±£¬Ïñ¸Ððҩ¡¢½âÈÈÕòÍ´¼Á¡¢ÑÛÒ©Ë®£¬¶àÊôÓÚÖ¸¶¨µÚ2ÀàºÍµÚ2¡¢3ÀàÒ½Ò©Æ·¡£¾¡¹ÜÕâЩҩƷÔÚÈÕ±¾¶¼²»ÄÑÂòµ½£¬µ«·þÓÃʱ»¹Ðè¶àÁô¸öÐÄÑÛ£¬ÌرðÊÇ¿ÉÄܺ¬Óжùͯ¡¢Ôи¾½û¼É³É·ÖµÄÖ¸¶¨µÚ2ÀàÒ½Ò©Æ·¡£ËäÈ»ÈÕ±¾¶ÔÓÚÒ©ÎïµÄ·ÖÀà¿´ËƸ߶ÈÖÜÈ«£¬ÈÃÈ˲»Ã÷¾õÀ÷£¬µ«ÔÚÏúÊÛʱ²»Ãâ´æÔÚһЩ²»ÖÜÖ®´¦¡£ÒòΪºÜ¶àÓοÍÂòÒ©µÄʵ¼Ê³¡¾°ÊÇÒ©×±µê£¬ºÍÖйúÒ©µêÊÇÒ©µê£¬»¯×±Æ·µêÊÇ»¯×±Æ·µê²»Í¬£¬µ±Ò©Æ·Ó뻯ױƷ¡¢Áãʳ¹²Í¬°ÚÔÚÒ»Æð£¬ÈËÔÚ¹ºÎïÀÖȤ±»¼«´ó³Ì¶È¼¤·¢µÄͬʱ£¬Ò²·ÅËÉÁ˶ÔÒ©Æ·°²È«µÄ¾¯Ìè¡£»¹ÓеÄÒ©Æ·°ü×°ÏÊÑÞ¿É°®£¬ÇÒ¼Ó³ÖÁËÃæ°ü³¬ÈË¡¢¶ßÀ² A Ãεȴó¼ÒÊìϤµÄ IP £¬Ê¹µÃÏ൱¶àÈË°ÑÒ©µÄ±¾ÖÊÅ×ÖîÄԺ󡣶øÒ©×±µêµÄµ¼¹ºËäÈ»ÓïÑÔ¼¼ÄܵãÂú£¬µ«¶ÔÒ©Îï½û¼É·½ÃæÆäʵ²¢²»Ì«¶®£¬¿´¼ûÓοÍÖ»»á·è¿ñÍÆÏú£¬ÏÊÉÙ̸¼°Ò©Îï·ÖÀà¡¢×¢ÒâÊÂÏ²¢Î´¾¡µ½ÌáÐÑ»¼ÕߺÏÀíÓÃÒ©µÄÒåÎñ¡£ÓÉÓÚÓïÑÔ±ÚÀÝ£¬Âò»Ø¹úºó»áÖ÷¶¯ÔĶÁҩƷ˵Ã÷Ê顢ʹÓýû¼É¡¢Ó÷¨ÓÃÁ¿µÈ¹Ø¼üÐÅÏ¢µÄÈËÒ²ÊÇÉÙÊý£¬ÓÚÊÇDZÔڵݲȫ·çÏÕ£¬Æ©Èç¹ýÁ¿¡¢½û¼É¡¢¹ýÃôµÈÎÊÌâ¾ÍÕâÑù±»ºöÊÓ¡£¹ýÈ¥ÕâЩÄ꣬¡°ÈÕ±¾ÍøºìÉñÒ©¡±ÔçÒÑÊÇÉ罻ƽ̨Éϲ»ÉÙ²©Ö÷µÄÁ÷Á¿ÃÜÂë¡£ºÜ¶àÈËÈ¥ÈÕ±¾Ò©×±µê²ÉÂò±äµÃ¸ü¾ßÕë¶ÔÐÔ£¬ÄÜ¿ìËÙ׼ȷÕÒµ½ÕæÕý¡°ºÃÓõġ±Ò©Æ·£¬²»ÔÙÃþϹ¡£¾ÍÁ¬ÔÝʱȥ²»ÁËÈÕ±¾µÄÈË£¬Ò²ÔÚͨ¹ýº£Íâ¿ç¾³Æ½Ì¨»òÕßÕÒ´ú¹ºÂò¡£µ«ÕýÊÇÕâЩ²»×¨ÒµµÄÖֲݣ¬Îóµ¼´ó¼ÒÈÕ±¾ÍøºìÉñÒ©¡°Ã»ÓÐÈκθ±×÷Óᱡ°¿ÉÒÔµ±ÈÕ³£±£½¡Æ·Ê¹Óá±£¬½ø¶ø¿ÉÄÜÄð³É´ó»ö¡£ËùÒÔ£¬Ï´ÎÔÙÔÚÈÕ±¾Ò©×±µêѪƴÕâЩ²©Ö÷°²ÀûµÄ¡°ÍøºìÉñÒ©¡±Ê±£¬¼ÇµÃ¶àÁô¸öÐÄÑÛ£¬²»ÒªÇáÐÅÄ°ÉúÒ©Îï¡£Èç¹ûÄãÎÊÎÒÓÐʲô±Ü¿Ó½¨Ò飬ÎҵĻشðÊÇ£ºÈƵÀ¡°Íøºì¡±¡£±¾ÎÄ¿ÆѧÐÔÒÑÓÉÅ®Íõ´óѧ²¡Àí¼°·Ö×Óҽѧ˶ʿÎéÀöÇàÉóºË²Î¿¼×ÊÁÏ£º[1] Ѧ¾§. (2024). ¸°ÈÕ¡°Þ¶Ñò롱£¿ÈÕ±¾³É×î»ð³ö¾³ÓÎÄ¿µÄµØ. ÅìÅÈÐÂÎÅ. Retrieved 28 May 2024 from https://mp.weixin.qq.com/s/8MCEZT6yTuNULc6FKMNZxg.[2] СÁÖÖÆÒ©Öêʽ»áÉç. (2024). ¼tüLévßBÑuÆ·¤ÎʹÓÃÖÐÖ¹¤Î¤ªîŠ¤¤¤È×ÔÖ÷»Ø…§¤Î¤ªÖª¤é¤». Retrieved 28 May 2024 from https://www.kobayashi.co.jp/info/20240322/.[3] Cicero, A. F. G., Colletti, A., Bajraktari, G., Descamps, O., Djuric, D. M., Ezhov, M., Fras, Z., Katsiki, N., Langlois, M., Latkovskis, G., Panagiotakos, D. B., Paragh, G., Mikhailidis, D. P., Mitchenko, O., Paulweber, B., Pella, D., Pitsavos, C., Reiner, ?., Ray, K. K., Rizzo, M., ¡ Banach, M. (2017). Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutrition reviews, 75(9), 731¨C767.[4] ÈÕ±¾ºñÉúÀͶ¯Ê¡. (2024). ÔÒòÎïÙ|¤ÎÌض¨¤Ë¤Ä¤¤¤Æ. Retrieved 28 May 2024 from https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/shokuhin/daietto/index.html.[5] Government of Canada. (2019). Health Canada seized three unauthorized eye drop products from Floy Beauty stores in Toronto, Ontario, because they may pose serious health risks. Retrieved 28 May 2024 from https://recalls-rappels.canada.ca/en/alert-recall/health-canada-seized-three-unauthorized-eye-drop-products-floy-beauty-stores-toront.[6] ²ÎÌìÖÆÒ©Öêʽ»áÉç. (2013). ÓÃÓÚÑÛÆ£ÀÍ¡¢³äѪ Sante FX NEO ˵Ã÷Êé.[7] Therapeutic Goods Administration. (2022). Consultation: Proposed amendments to the Poisons Standard ¨CACCS, ACMS and joint ACCS/ACMS meetings, June 2022.[8] ¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾Ö. (2024). Êý¾Ý²éѯ. Retrieved 28 May 2024 from https://www.nmpa.gov.cn/datasearch/home-index.html.[9] U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-Approved Drugs. Retrieved 28 May 2024 from https://www.fda.gov/about-fda.[10] ¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾Ö. (1999). ¹ØÓÚÎÒ¹úʵʩ´¦·½Ò©Óë·Ç´¦·½Ò©·ÖÀà¹ÜÀíÈô¸ÉÒâ¼ûµÄ֪ͨ. Retrieved 28 May 2024 from https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/19990419010101154.html?type=pc&m=.[11] ÈÕ±¾OTCҽҩƷлá. (2024). OTCÒ½ËaÆ·¤ÎØœ‰Ó·½·¨¤Ë¤Ä¤¤¤Æ. Retrieved 28 May 2024 from https://www.jsmi.jp/selfmedication/basic/sell.html.